---
title: "MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295399066.md"
description: "On August 10, 2026, MoonLake Immunotherapeutics, a biotechnology company trading on NASDAQ under the symbol MLTX, shared promising findings from the Phase 3 IZAR-1 trial for sonelokimab. The study targeted biologic-naïve adults grappling with active psoriatic arthritis (PsA). The results were positive. Additionally, the company disclosed its financial performance for the second quarter of 2026 in Zug, Switzerland. MoonLake specializes in developing advanced treatments for inflammatory conditions."
datetime: "2026-08-10T11:10:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295399066.md)
  - [en](https://longbridge.com/en/news/295399066.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295399066.md)
generator: "portal-rs"
---

# MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

On August 10, 2026, MoonLake Immunotherapeutics, a biotechnology company trading on NASDAQ under the symbol MLTX, shared promising findings from the Phase 3 IZAR-1 trial for sonelokimab. The study targeted biologic-naïve adults grappling with active psoriatic arthritis (PsA). The results were positive. Additionally, the company disclosed its financial performance for the second quarter of 2026 in Zug, Switzerland. MoonLake specializes in developing advanced treatments for inflammatory conditions.

### Related Stocks

- [MLTX.US](https://longbridge.com/en/quote/MLTX.US.md)

## Related News & Research

- [MoonLake's psoriatic arthritis drug meets key goals in late-stage trial](https://longbridge.com/en/news/295404482.md)
- [MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study](https://longbridge.com/en/news/295434879.md)
- [Coya Therapeutics posts September 2026 investor presentation on neurodegeneration pipeline](https://longbridge.com/en/news/297669200.md)
- [Zenas Biopharma outlines autoimmune disease pipeline in corporate presentation](https://longbridge.com/en/news/297813603.md)
- [C4 Therapeutics to present Phase 1 biomarker data on cemsidomide plus dexamethasone in multiple myeloma trial at IMS meeting](https://longbridge.com/en/news/297902451.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**